Displaying items by tag: department of medicine

New drug may slow the progression of chronic kidney disease in type 2 diabetics, increase kidney function and stave off dialysis.

With the acquisition, UAB takes a significant step toward making sophisticated cell therapy a part of patient care.

The risk factors for stroke in the South also may be responsible for cognitive decline.

By mapping a patient’s genome, and their tumor’s, with whole-genome sequencing, physicians can use more targeted therapies.

Tigatuzumab, developed at UAB with Daiichi-Sankyo, targets aggressive, hard-to-treat tumors that make up 25 percent of all breast cancers

Page 32 of 32